Dr. Giselle Sholler, principal investigator and pediatric oncologist from Vermont Cancer Center, presented important information regarding the newly opened "Phase 1 Trial of TPI 287 as a Single Agent and in Combination with Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma." This presentation was intended for parents and caregivers of children with refractory or recurrent neuroblastoma and medulloblastoma on behalf of the Neuroblastoma Foundation. Dr. Sholler provided an overview of the preclinical research leading up to the trial. She also discussed the rationale behind the trial and the eligibility requirements. Parents of children that have participated in this trial were also available to share their experiences. The presentation was followed with a question and answer session. This presentation and question and answer session was originally published on Wednesday, August 26, 2009 at 12:00PM CST.